Best length of daratumumab maintenance for light-chain (AL) amyloidosis
Evaluating Maintenance In Light chain Amyloidosis (EMILIA)
This project compares shorter (6 months) versus longer (18 months) daratumumab maintenance for people with AL amyloidosis who have responded to daratumumab-CyBorD induction.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11247977 on NIH RePORTER |
What this research studies
If you have light-chain (AL) amyloidosis and achieved a good blood response after initial daratumumab-CyBorD therapy, this trial would randomly assign you to receive daratumumab maintenance for either 6 months or 18 months. Doctors will monitor blood markers, organ function, and side effects over time to see how long the response lasts and whether organs recover. The study uses a pragmatic design to reflect real-world care while comparing the two maintenance lengths. The goal is to find whether shorter maintenance can keep benefits while lowering treatment burden or whether longer maintenance gives better outcomes.
Who could benefit from this research
Good fit: Adults with AL (light-chain) amyloidosis who achieved an adequate hematologic response after daratumumab-CyBorD induction would be the ideal candidates.
Not a fit: Patients who have not received daratumumab-CyBorD induction, who did not achieve a good hematologic response, or those with other non-AL forms of amyloidosis would not be expected to benefit from or be eligible for this trial.
Why it matters
Potential benefit: If successful, this could show the optimal maintenance duration to preserve responses and organ recovery while potentially reducing treatment time and side effects.
How similar studies have performed: The phase III ANDROMEDA trial showed daratumumab-CyBorD induction improves hematologic responses but included non-randomized maintenance, so randomized evidence on optimal maintenance duration is currently lacking.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kourelis, Taxiarchis — Mayo Clinic Rochester
- Study coordinator: Kourelis, Taxiarchis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.